» Articles » PMID: 17197121

Immediate Postoperative Radiotherapy in Residual Nonfunctioning Pituitary Adenoma: Beneficial Effect on Local Control Without Additional Negative Impact on Pituitary Function and Life Expectancy

Overview
Specialties Oncology
Radiology
Date 2007 Jan 2
PMID 17197121
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To demonstrate the benefit of immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma (NFA) in perspective to the need for hormonal substitution and life expectancy.

Methods And Materials: Retrospective cohort analysis of 122 patients, operated for NFA between 1979 and 1998. Recurrence was defined as regrowth on computed tomography or magnetic resonance imaging. The occurrence of hormonal deficiencies was defined as the starting date of hormonal substitution therapy.

Results: Seventy-six patients had residual NFA after surgery and received immediate postoperative radiotherapy (Group 1); three patients developed a recurrence, resulting in a 95% local control rate at 10 years. Twenty-eight patients had residual NFA after surgery, but were followed by a wait-and-see policy (Group 2). Sixteen developed a recurrence, resulting in a local control rate of 49% at 5 years and 22% at 10 years (p < 0.001 compared with Group 1). There were no differences between Group 1 and 2 regarding the need for substitution with thyroid hormone, glucocorticoids, and sex hormones before first surgery, directly after surgery and at end of follow-up. There were no differences in hormone substitution free survival between Group 1 and Group 2 during the study period after first surgery. Life expectancy was similar in Group 1 and 2, and their median life expectancy did not differ from median life expectancy in the general population.

Conclusions: Immediate postoperative radiotherapy provides a marked improvement of local control among patients with residual NFA compared with surgery alone, without an additional deleterious effect on pituitary function and life expectancy.

Citing Articles

Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations.

Korbonits M, Blair J, Boguslawska A, Ayuk J, Davies J, Druce M Nat Rev Endocrinol. 2024; 20(5):278-289.

PMID: 38336897 DOI: 10.1038/s41574-023-00948-8.


Postsurgical outcomes of nonfunctioning pituitary adenomas: a patient-level meta-analysis.

Fong K, Lim M, Fu S, Low C, Chan Y, Deepak D Pituitary. 2023; 26(4):461-473.

PMID: 37389776 DOI: 10.1007/s11102-023-01335-2.


Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?.

Charleux T, Vendrely V, Huchet A, Trouette R, Ferriere A, Tabarin A Radiat Oncol. 2022; 17(1):165.

PMID: 36229880 PMC: 9559766. DOI: 10.1186/s13014-022-02133-z.


Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report.

Lin S, Han C, Lou X, Wu Z Front Endocrinol (Lausanne). 2022; 13:955100.

PMID: 35983516 PMC: 9379538. DOI: 10.3389/fendo.2022.955100.


Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions.

Lu L, Wan X, Xu Y, Chen J, Shu K, Lei T Diagnostics (Basel). 2022; 12(4).

PMID: 35454025 PMC: 9024548. DOI: 10.3390/diagnostics12040977.